Recent Updates
Recently added Catalysts
PHAR Positive Sentiment

Pharming Group to participate in November investor conference

Key Takeaway: Pharming Group N.V. will participate in the Jefferies London Healthcare Conference from November 19-21, 2024. CEO Sijmen de Vries is scheduled to present on November 20. The event will include a live webcast and a replay available on Pharming's website. This participation highlights Pharming's commitment to engaging with investors and showcasing its portfolio of products and therapies.
Price reaction · baseline $8.3327 (2024-11-04 close) · hit after-hours · clean, no other PHAR news in the window
day 0 close · peak
-2.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Pharming Group will present at a notable investor conference.
  • The conference offers opportunities for one-to-one meetings with management.
  • Pharming is actively engaging with investors to showcase its innovations.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
9.3%
average across 4 past catalysts
Lead asset
Recombinant human C1 inhibitor
Phase 3 · Hereditary Angioedema

Full Press Release Details

Leiden, the Netherlands, November 5, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of November:
Jefferies London Healthcare Conference 2024, London, U.K., November 19-21
Sijmen de Vries, Chief Executive Officer, will present on Wednesday, November 20 at 08:00 GMT/09:00 CET. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website.
For more information about this conference, or to schedule a one-to-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your Jefferies representative.
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
FTI Consulting, London, United Kingdom
Victoria Foster Mitchell/Alex Shaw/Amy Byrne
LifeSpring Life Sciences Communication, Amsterdam, the Netherlands
T: +31 6 53 81 64 27
Pharming attending Investor Conferences November 2024_EN_05NOV24

Frequently Asked Questions

When is Pharming participating in the Jefferies Conference?

Pharming will participate in the Jefferies London Healthcare Conference from November 19-21, 2024.

Who will present for Pharming at the conference?

Sijmen de Vries, the CEO, will present on November 20 at 08:00 GMT.

How can I watch Pharming's presentation?

The presentation will be available via live webcast and replay on Pharming's website.

How can I contact Pharming's Investor Relations?

For inquiries, email Pharming's Investor Relations team at investor@pharming.com.

What does Pharming Group specialize in?

Pharming specializes in protein replacement therapies and precision medicines for rare diseases.

Last updated: Nov 5, 2024